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Abstract
Background—In non-experimental comparative effectiveness research using healthcare 
databases, outcome measurements must be validated to evaluate and potentially adjust for 
misclassification bias. We aimed to validate claims-based myocardial infarction algorithms in a 
Medicaid population using an HIV clinical cohort as the gold standard.
Methods—Medicaid administrative data were obtained for the years 2002–2008 and linked to 
the UNC CFAR HIV Clinical Cohort based on social security number, first name and last name 
and myocardial infarction were adjudicated. Sensitivity, specificity, positive predictive value, and 
negative predictive value were calculated.
Results—There were 1,063 individuals included. Over a median observed time of 2.5 years, 17 
had a myocardial infarction. Specificity ranged from 0.979–0.993 with the highest specificity 
obtained using criteria with the ICD-9 code in the primary and secondary position and a length of 
stay ≥ 3 days. Sensitivity of myocardial infarction ascertainment varied from 0.588–0.824 
depending on algorithm. Conclusion: Specificities of varying claims-based myocardial infarction 
ascertainment criteria are high but small changes impact positive predictive value in a cohort with 
low incidence. Sensitivities vary based on ascertainment criteria. Type of algorithm used should 
be prioritized based on study question and maximization of specific validation parameters that will 
minimize bias while also considering precision.
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Large health care databases are useful for conducting non-experimental comparative 
effectiveness research. While not perfect, the population is often closer to ideal than ad hoc 
studies because it is less selected, information on drug exposure in these sources is good for 
prescription drugs in the outpatient setting, the data is generally available, and their large 
sample size provides an opportunity to examine rare outcomes.1 As these data are collected 
primarily for administrative purposes and not for research, however, outcome measurements 
should be validated to quantify or minimize bias due to misclassification.
Measures of accuracy, sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) are used to quantify misclassification. Sensitivity and specificity 
generally assess outcome and exposure misclassification while PPV and NPV are most often 
used for population selection. There is a tradeoff between maximizing sensitivity versus 
specificity in comparative effectiveness and safety studies and choice of measure should be 
based on the overarching study question.2 In studies estimating relative effects, specificity is 
the most important outcome misclassification measure because a perfect specificity will lead 
to unbiased relative risk estimates even if sensitivity is low. 3 A high sensitivity allows for 
identification of most events and reduces bias of effect measures on the absolute scale (risk 
difference [RD] or number needed to treat).4 Many validation studies start with a large 
administrative healthcare database where algorithms to define events are validated against a 
gold standard (e.g., medical records). These studies are only able to calculate PPVs and not 
sensitivity and specificity as they do not have access to the gold standard population without 
the event (true negatives).
Observational clinical cohort studies have contributed substantially to our understanding of 
the effectiveness of different antiretroviral treatments for HIV clinical management.5–10 
Similarities and differences between clinical cohort studies and other more traditional 
observational studies (e.g. interval cohorts) have been discussed elsewhere.11 Briefly, 
participants in clinical cohort studies are enrolled as they seek or receive care and the 
medical record is the source for information collected on the participants. Despite their use 
to examine the effect of treatments in a real world setting, these studies may not reach 
adequate person-time of follow-up required to study rare events.
The accuracy of myocardial infarction (MI) ascertainment in administrative healthcare data 
has been assessed; however, most studies only present PPV due to the lack of true negatives 
needed to estimate sensitivity and specificity. 12–17 Further, some validation studies used 
algorithms to identify MI events that may now be outdated due to changes in patient 
treatment as well as healthcare service and reimbursement.15–17 For example, many current 
MI ascertainment algorithms contain a length of stay criteria ≥ 3 days. Analyses of hospital 
discharge records from Minnesota and New England suggest that the median length of stay 
for patients hospitalized with MI is decreasing.18,19 These observations justify a periodic 
reassessment and validation of MI algorithms used for outcome ascertainment as changes 
occur in systems for diagnostic coding, healthcare practices and reimbursement 
policies. 20,21
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By linking clinical cohort data to administrative healthcare data, it is possible to validate 
algorithms defining health outcomes of interest. In this study, we used the UNC HIV CFAR 
Clinical Cohort (UCHCC) study and the North Carolina (NC) Medicaid administrative data, 
to validate different claims-based definitions of MI within an HIV-infected population.
Methods
Study Population
We used the UCHCC and NC Medicaid administrative data for this validation study. The 
UCHCC is a dynamic clinical cohort study initiated in 2000 and includes all HIV-infected 
patients that are ≥18 years of age unless they are unable or unwilling to provide written 
informed consent in English or Spanish. The cohort includes data from different sources 
including existing hospital electronic databases, medical chart abstractions, in-person 
interviews, and data from federal agencies including mortality information. UCHCC 
participants are not seen at exact regular intervals, but rather as indicated by clinical care.
The Medicaid program is a joint state and federally funded program providing healthcare 
benefits to individuals of low income. Individuals qualify based on age, disability, income 
and financial resources.22 The Medicaid data contains health care service reimbursement 
information including doctor visits, hospital care, outpatient visits, treatments, emergency 
use, prescription medications, and diagnoses, procedures and provider information. These 
data also include reimbursement information for Medicaid patients also enrolled in Medicare 
(dually eligible beneficiaries). We included all HIV-infected NC Medicaid beneficiaries and 
those dually eligible beneficiaries ≥ 18 years of age with Medicaid enrollment between 
January 1, 2002 and December 31, 2008. HIV patients were identified in the Medicaid 
administrative data using the following definition: an ICD-9 code of 042 in any position or a 
prescription of any of the 27 FDA approved antiretrovirals between 2002 and 2008. 
Antiretrovirals were identified in the administrative data through National Drug Codes 
(NDC). Patients enrolled both in the UCHCC and Medicaid at any point between 2002 and 
2008 formed the validation sample. For these patients we merged the UCHCC and the 
Medicaid administrative data based on social security number, first and last name.
Validation study mechanics
We synchronized periods of continuous Medicaid eligibility with the UCHCC and included 
all patients in both Medicaid and UCHCC between 2002 and 2008 with at least 30 days of 
observation time in both data sources. Patients contributed observed time from the last of (i) 
January 1, 2002, (ii) entry into the UCHCC or (iii) start of Medicaid enrollment. Patients’ 
time was included until the first of (i) December 31, 2008, (ii) 12 months following the last 
documented CD4 count or HIV RNA measurement in the UCHCC, or (iii) more than 30 
days without Medicaid enrollment. If a patient was lost to HIV care in the UCHCC (i.e. 
more than 12 months without a documented CD4 count or HIV RNA measurement) or lost 
Medicaid coverage for more than 30 days but then reinitiated HIV care or Medicaid 
enrollment, this time at risk was not considered in these analyses. Among patients who died, 
observed time was stopped on the date of death.
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We included all patients that had either a definite or probable MI as defined in the UCHCC 
and Medicaid data sources during the study period. In an initial validation analysis, we 
included the first MI event documented in either the UCHCC or Medicaid occurring during 
the observed period and did not impose any restriction on dates of events when assessing 
validation parameters. In a secondary analysis, we accounted for multiple MI events per 
patient, timing of the event, and length of observed time in each source by creating 
standardized time increments (3,6,12,24 months) within the previously defined observed 
period. In order to maintain synchronicity between data sources and to account for differing 
lengths of follow-up time, if the observed period ended in the middle of the defined 
increment, that observation was not included in the analysis. Time increments were 
determined based on length of continuous follow-up often required for comparative 
effectiveness studies. Due to sample size constraints, we did not consider time increments > 
24 months.
Myocardial Infarction definition—UNC CFAR HIV Clinical Cohort (Gold Standard)
Myocardial infarction events were initially identified in the UCHCC through medical chart 
abstraction and adjudicated by health care personnel. The MI event definition expands upon 
the World Health Organization definition and includes serum markers, ECGs and chest pain 
criteria. 23,24
Myocardial Infarction definition—Medicaid Administrative Claims
As we were interested in validation of incident MI events and most new MI events present 
to the hospital versus an outpatient setting, we used inpatient claims. The administrative data 
included claims for patients enrolled in Medicaid as well as those who were dually eligible 
for Medicaid and Medicare. Our initial MI event definition included a diagnosis code 
(ICD-9-CM) of 410 in the 1st or 2nd position and a length of stay ≥ 3 days as has been used 
in previous validation studies. 15–17 We then used varying algorithms to identify MI events 
to determine the algorithm that would best identify MI events in this population. The 12 
algorithms considered included varying: (i) ICD-9 code 410.xx in 1st or 2nd position, versus 
any position; (ii) length of stay as any number of day, ≥ 1 day, and ≥ 3 days; and (iii) 
inclusion of diagnosis related group (DRG) codes 121, 122 and 123.
Statistical Analysis
We examined basic baseline demographic and clinical characteristics of the NC Medicaid 
population, the UCHCC and the validation sample for the enrollees identified with a MI in 
the gold standard. We then cross-tabulated MI events identified in both cohorts based on the 
definitions outlined above to estimate sensitivity (proportion of true MI events identified in 
Medicaid among all gold standard defined MI events), specificity (proportion of true non-
events identified in Medicaid among all gold standard defined non- events), PPV (proportion 
of true MI events identified in Medicaid among all MI events identified in Medicaid) and 
NPV (proportion of true non-events identified in Medicaid among all non-events identified 
in Medicaid). Exact binomial 95% confidence intervals (CI) quantified the precision around 
each validation measure.25 For our secondary analysis, intercept only generalized estimating 
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equation models with a binomial distribution, independent correlation structure and logit 
link estimated sensitivity and specificity. These characteristics were calculated for the 3, 6, 
12 and 24 month time increments.
Finally, we explored the impact of outcome misclassification on relative risk and absolute 
risk estimates in a hypothetical population of 1,100 individuals, a baseline probability of 
exposure of 0.09 and a risk of MI of 0.1 in the exposed and 0.08 in the unexposed to a 
hypothetical risk factor (true Risk Ratio [RR]: 1.25, true Risk Difference [RD]: 0.02). We 
used sensitivities and specificities estimated from our validation study to calculate the 
expected percent bias in the estimated RR and RD under different definitions of MI 
assuming no misclassification of exposure and non-differential outcome misclassification. 
We used the following equations to calculate the observed RR and RD:
where
a=sensitivity*proportion exposed*risk in exposed + (1-specificity)*proportion 
exposed*(1-risk in exposed)
b=(1-sensitivity)*proportion exposed*risk in exposed + specificity*proportion 
exposed*(1-risk in exposed)
c=sensitivity*(1-proportion exposed)*incidence in the unexposed + (1-specificity)*(1- 
proportion exposed)*(1-risk in unexposed)
d=(1-sensitivity)*(1-proportion exposed)*incidence in the unexposed + specificity*(1-
proportion exposed)*(1-risk in unexposed)
We quantified the percent bias for both the RR and RD using the following equation:
All analyses were conducted using SAS version 9.2 or Intercooled Stata11. The study was 
approved by the [REDACTED FOR BLINDING] on the Protection of the Rights of Human 
Subjects.
Results
Between 2002 and 2008 there were 1,134,986 NC Medicaid beneficiaries ≥ 18 years of age 
of whom 13,006 patients were HIV-infected based on an ICD-9 or antiretroviral use criteria. 
Of 2,340 HIV-infected patients in the UCHCC who received care between 2002 and 2008, 
1,204 patients were also Medicaid beneficiaries. There were 141 UCHCC and Medicaid 
beneficiaries that were not included as they either did not have sufficient follow-up time in 
either data source or the period of Medicaid eligibility did not overlap with follow-up time 
in the UCHCC, leaving 1,063 patients included in the validation sample. (Figure 1) The 
median length of observed time for the validation population was 2.5 years (Interquartile 
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Range: 0.9, 4.7; Full range: 0.2, 7.0). The distribution of most demographic and clinical 
characteristics of the overall Medicaid population, UCHCC and validation sample were 
similar. (Table 1) The overall Medicaid population and validation sample had a greater 
proportion of black, women and younger patients when compared to the UCHCC while the 
validation sample had a larger proportion of intravenous drug users. Clinically, patients 
included in the validation sample had similar log HIV RNA and CD4 cell counts at entry 
into care at UNC. In the validation sample, 17 patients had a MI event that occurred during 
their observation period and there were 19 total MI events.
The validation test characteristics comparing MI events in the UCHCC with those identified 
in the Medicaid data using varying algorithms are displayed in table 2. The current most 
frequent algorithm used to identify MI events in administrative data, ICD-9 code in the 1st or 
2nd position and a length of stay ≥ 3 days, resulted in a calculated sensitivity of 0.588 (95% 
CI: 0.329, 0.816) and a specificity of 0.994 (95% CI: 0.988, 0.998). Removing the length of 
stay criteria increased sensitivity to 0.647 (95% CI: 0.383, 0.857) and decreased specificity 
to 0.988 (95% CI: 0.980, 0.994). The position of the diagnosis code also influenced 
validation parameters. Allowing the ICD 9-code 410 to be present in any of the nine ICD-9 
code positions while keeping the ≥ 3 day length of stay requirement increased the sensitivity 
of MI identification to 0.765 (95% CI: 0.501, 0.932). Removing the position and length of 
stay requirement resulted in the highest sensitivity and lowest specificity of event 
ascertainment (Sensitivity=0.823 [95% CI: 0.566, 0.962]; Specificity=0.982 [95% CI: 0.972, 
0.999]). Overall PPVs were low for all of the algorithms explored (Range: 0.438–0.625) 
while NPVs remained consistently high (0.993–0.997). The addition of DRG codes 121, 
122, 123 did not appreciably change validation parameters (data not shown).
We also examined the effect of length of observation, timing of events as well as multiple 
MI events per patient. For this analysis we used the most commonly used MI ascertainment 
criteria in the literature (ICD-9 code in 1st or 2nd position and a length of stay ≥ 3 days). 
Since we required the entire length of time for each time increment, the number of unique 
patients included decreased as increments increased from 3 to 24 months (1,007 patients to 
598 patients respectively). When allowing for a 24 month increment of observed time, 
sensitivity and specificity measurements were similar to those in the first validation analysis 
(Sensitivity=0.538 [95% CI: 0.268, 0.788]; Specificity=0.998 [95% CI: 0.993, 0.999]). 
Sensitivity was lowest when allowing for only a three month period of eligibility for the 
event to occur in both data sources (0.444 [95% CI: 0.250, 0.658]), and increased for the 6 
and 12 month incremental periods (0.516 [95% CI: 0.314, 0.713] and 0.600 [95% CI: 0.338, 
0.815] respectively). (Figure 2) A similar relationship between length of observed time and 
sensitivity and specificity was observed for the other MI algorithms. For all algorithms, the 
maximum sensitivity was observed when the standardized 12 month time increment was 
used (data not shown).
Table 3 displays the effect of outcome misclassification in a hypothetical population using 
sensitivity and specificity measures from the following algorithms: 1) ICD-9 code 410 in the 
1st or 2nd position and length of stay ≥ 3 days 2) ICD-9 code 410 in 1st or 2nd position and a 
length of stay ≥ 1 day and 3) ICD-9 code 410 in any position and any length of stay. Given a 
population of 1,100 individuals, a baseline probability of exposure to a hypothetical risk 
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factor of 0.09 and a risk of MI of 0.1 in the exposed and 0.08 in the unexposed (true RR: 
1.25, true RD: 0.02); a sensitivity of 0.588 and a specificity of 0.994 will result in an 
observed RR of 1.21 and an observed RD of 0.015. A sensitivity of 0.824 and a specificity 
of 0.982 would result in a RR of 1.10 and a RD of 0.009. An assessment of bias reveals that 
the percent bias is highest for both relative and absolute measures when specificity is the 
lowest.
Discussion
We examined sensitivity, specificity, PPV and NPV of various algorithms to identify MI 
events among HIV-infected individuals enrolled in the NC Medicaid program relying on 
events adjudicated in the UCHCC as the gold standard. We found that using our best 
algorithm for relative effect measures, we achieved a specificity of 0.994 translating to a 
bias of around 11% based on plausible parameter values for a study of antiretrovirals on risk 
of MI using administrative healthcare data. In general specificity measures using all 
ascertainment algorithms were high (0.982–0.994), however, even small deviations in 
specificity increased bias of effect measures.
Compared to other studies, the sensitivity of a commonly used algorithm to identify MIs 
(ICD-9 code 410 in the 1st or 2nd position and length of stay ≥ 3 days), was low in our study 
(0.59). Other studies reported sensitivities ranging from 0.65–0.83.13,26 The observed 
sensitivities may be explained by our study population and ICD-9 code position. HIV 
patients are often admitted to the hospital for HIV-related and general medical comorbidities 
and an MI event occurring during a hospital stay may not get coded in the 1st or 2nd ICD-9 
code position. Therefore, an expansion of the criteria to include all ICD-9 code positions 
would increase the sensitivity of the ascertainment criteria as we observed. Rosamond et al. 
noted that sensitivities of ICD-9 code 410 also have declined over time; in part due to 
changes in diagnostic practices and the use of differing algorithms for defining MI in the 
gold standard. 27
We investigated other diagnoses in the Medicaid data or the UCHCC for patients that 
remained misclassified despite the use of the most sensitive or most specific algorithms 
(three false negatives and six false positives respectively). Using the most sensitive 
algorithm, three patients had a MI in the gold standard. Two of these patients had ICD-9 
codes for non-MI, cardiovascular related conditions, on or around the diagnosis date 
identified by the gold standard (unspecified chest pain and precordial pain; coronary 
atherosclerosis of native coronary artery). The third patient did not have any ICD-9 codes 
related to cardiovascular disease conditions coded on or around the date of diagnosis in the 
UCHCC. Using the most specific algorithm, there were six patients with a claim for a MI in 
the administrative data that did not have an MI in the UCHCC. Five out of six of these 
patients did have other, non-MI, cardiovascular related conditions in the UCHCC. The sixth 
patient did not have any cardiovascular conditions noted but did have a history of drug 
abuse.
We also addressed the impact of varying lengths of observed time, timing of events, and 
multiple MI events on ascertainment criteria performance. Sensitivity was lowest for the 
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shortest time increment indicating that dates recorded for events in the Medicaid data were 
not the same as dates recorded in the UCHCC. Sensitivities for the 6 and 12 month intervals 
were similar to those calculated in the first validation study. The decrease in sensitivity for 
the 24 month time frame was likely due to the reduction in number of patients with at least 
24 months of observed time for analysis. These results suggest that a requirement for a full 
12 months of eligibility in Medicaid may maximize the sensitivity of claims-based MI 
identification algorithm.
Positive predictive values calculated using the differing MI ascertainment algorithms in our 
study were substantially lower than values obtained from previous studies (0.93–
0.97). 12,15–17 These results are likely due to the low prevalence of MI in this population. 
However, while PPV is an important measure for some research questions, this measure has 
less importance in the context of comparative effectiveness research. Nevertheless, the low 
PPVs suggest that the administrative healthcare data used here may not be ideal for the 
selection of a study cohort.
Chubak et al. and Setoguchi et al. explored bias related to outcome misclassification in a 
hypothetical population (Chubak) and a Medicare population (Setoguchi). 28,29 Their results 
quantified outcome misclassification bias on a relative scale, but did not address 
misclassification bias on an absolute scale. Often absolute measures, like the RD, are used in 
comparative safety and effectiveness studies; therefore addressing the impact of less than 
perfect specificity and sensitivity on both types of effect measures is warranted. In our 
hypothetical example, as expected, deviations from perfect specificity led to biased results 
on the relative scale while increases in sensitivity decreased bias on the absolute scale. 
However, both sensitivity and specificity influenced absolute measures. While a perfect 
specificity decreases the bias of relative effect measures, the reduction of the number of 
cases identified may decrease precision around estimates substantially. Therefore, the choice 
of ascertainment algorithm used should be prioritized based on the study question, using the 
specific validation parameter that will minimize bias while maximizing precision. For this 
HIV Medicaid population, it may be important to use an algorithm that expands the ICD-9 
code position requirement to maximize sensitivity with minimal decreases in specificity.
Our study has limitations. The number of events obtained for validation was low which 
influenced the precision around our measurements. Further, we intentionally conducted this 
study in a Medicaid HIV population limiting the generalizability of these algorithms to other 
populations or data sources. Despite these limitations, our study has important implications. 
Since this population includes patients seeking care throughout the state of NC, we will be 
able to examine the effects of antiretrovirals on MI in a more generalized population. Each 
ascertainment algorithm had relatively high specificity and can be used to conduct 
comparative effectiveness studies examining the relationship between antiretroviral use and 
MI outcomes in the NC Medicaid population. Finally, the measures of validity reported here 
may be used by other researchers to assess the role of outcome misclassification in studies 
using administrative healthcare databases.
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Generation of the sample population used to validate myocardial infarction outcomes 
ascertained from the North Carolina Medicaid Administrative Data. The North Carolina 
Medicaid data was linked to the UNC CFAR HIV Clinical Cohort (UCHCC) study via 
social security number, last name and first name.
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Sensitivity and false positive rate for claims-based identification of myocardial infarctions 
allowing for varying periods of continuous eligibility (3, 6, 12, 24 months). Myocardial 
infarction events were identified by ICD-9 code 410 in the 1st or 2nd position and a length of 
stay ≥ 3 days.
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Table 1









 Female 5,918 (45.5) 706 (30.2) 437 (41.1)
Age at UCHCC/Medicaid entry, years
 <40 5,505 (42.3) 1,259 (53.8) 541 (50.9)
 40–50 4,699 (35.1) 783 (33.5) 389 (36.6)
 >50 2,802 (21.5) 298 (12.7) 133 (12.5)
Race
 White 2,740 (21.1) 738 (31.5) 229 (21.5)
 Black 9,221 (71.0) 1,369 (58.5) 757 (71.2)
 Hispanic 0 (0.0) 138 (5.9) 22 (2.1)
 Asian 68 (0.5) * 0 (0.0)
 Native American/Pacific Islander 169 (1.3) 42 (1.8) 32 (3.0)
 Other 0 (0.0) 48 (2.1) 22 (2.1)
 Unknown 808 (6.0) * *
Insurance at UCHCC entry
 Medicaid NA 572 (24.5) 475 (44.7)
 Medicare NA 133 (5.7) 54 (5.1)
 Other Public Insurance NA 149 (6.4) 71 (6.7)
 Private NA 630 (27.0) 117 (11.0)
 No Insurance NA 849 (36.3) 344 (32.4)
Men who have sex with Men (MSM)
 Yes NA 914 (39.1) 263 (24.7)
Intravenous Drug User (IDU)
 Yes NA 338 (14.0) 235 (22.1)
CD4 count (cells/μL) most proximal to UCHCC entry (median, IQR)† NA 310 (104, 507) 280 (73, 483)
log HIV RNA (copies/mL) most proximal to UCHCC entry (median, 
IQR)††
NA 4.4 (3.2, 5.0) 4.4 (3.4, 5.1)
*
Cell counts < 11 not displayed
**
<0.01 percent missing values for insurance status in the UCHCC and validation cohort respectively
†
<0.01 percent missing CD4 count values for UCHCC and the validation cohort respectively.
††
<0.01 percent missing log HIV RNA values for UCHCC and the validation cohort respectively.
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